

Plasmodium vivax clinical malaria is commonly observed in Duffy-negative Malagasy people

Didier Ménard^{a,b,1,2}, Céline Barnadas^{a,c,1}, Christiane Bouchier^d, Cara Henry-Halldin^c, Laurie R. Gray^c, Arsène Ratsimbaoa^e, Vincent Thonier^a, Jean-François Carod^f, Olivier Domarle^a, Yves Colin^g, Olivier Bertrand^g, Julien Picot^g, Christopher L. King^{c,h}, Brian T. Grimberg^c, Odile Mercereau-Puijalon^{b,2}, and Peter A. Zimmerman^{c,2}

^aInstitut Pasteur de Madagascar, Unité de Recherche sur le Paludisme, Antananarivo 101, Madagascar; ^bInstitut Pasteur, Unité d'Immunologie Moléculaire des Parasites, Centre National de la Recherche Scientifique Unité de Recherche Associée 2581, Paris 75724 cedex 15, France; ^cCenter for Global Health and Diseases, Case Western Reserve University, School of Medicine, Cleveland, OH 44106-7286; ^dInstitut Pasteur, Plate-forme Génomique, Paris 75724 cedex 15, France; ^eMinistère de la Santé, du Planning Familial et de la Protection Sociale, Direction de la Lutte contre les Maladies Infectieuses, Antananarivo 101, Madagascar; ^fInstitut Pasteur de Madagascar, Centre de Biologie Clinique, Antananarivo 101, Madagascar; ^gInstitut National de Transfusion Sanguine, Unité Mixte de Recherche-5 665 Inserm/Université Paris Diderot, Paris 75739 cedex 15, France; and ^hVeterans Affairs Research Service, Cleveland, OH 44106

Edited by Thomas E. Wellems, National Institutes of Health, Bethesda, MD, and approved February 22, 2010 (received for review October 29, 2009)

Malaria therapy, experimental, and epidemiological studies have shown that erythrocyte Duffy blood group-negative people, largely of African ancestry, are resistant to erythrocyte *Plasmodium vivax* infection. These findings established a paradigm that the Duffy antigen is required for *P. vivax* erythrocyte invasion. *P. vivax* is endemic in Madagascar, where admixture of Duffy-negative and Duffy-positive populations of diverse ethnic backgrounds has occurred over 2 millennia. There, we investigated susceptibility to *P. vivax* blood-stage infection and disease in association with Duffy blood group polymorphism. Duffy blood group genotyping identified 72% Duffy-negative individuals ($FY^*B^{ES}/*B^{ES}$) in community surveys conducted at eight sentinel sites. Flow cytometry and adsorption-elution results confirmed the absence of Duffy antigen expression on Duffy-negative erythrocytes. *P. vivax* PCR positivity was observed in 8.8% (42/476) of asymptomatic Duffy-negative people. Clinical vivax malaria was identified in Duffy-negative subjects with nine *P. vivax* mono-infections and eight mixed *Plasmodium* species infections that included *P. vivax* (4.9 and 4.4% of 183 participants, respectively). Microscopy examination of blood smears confirmed blood-stage development of *P. vivax*, including gametocytes. Genotyping of polymorphic surface and microsatellite markers suggested that multiple *P. vivax* strains were infecting Duffy-negative people. In Madagascar, *P. vivax* has broken through its dependence on the Duffy antigen for establishing human blood-stage infection and disease. Further studies are necessary to identify the parasite and host molecules that enable this Duffy-independent *P. vivax* invasion of human erythrocytes.

erythrocyte | evolution | DARC | Madagascar

During malaria fever therapy trials, performed to treat neurosyphilis (1920s to 1960s) and in experimental field trials, it was consistently demonstrated that Africans and African-Americans were highly resistant to *Plasmodium vivax* blood-stage malaria when challenged with human blood or mosquitoes infected with limited numbers of *P. vivax* strains (1–3). Following identification of the Duffy blood group (Fy; reviewed in Zimmerman, 2004) (4), population studies showed that individuals of African ancestry expressed neither Fy^a nor Fy^b antigens and were classified as Duffy negative, Fy(a–b–) (5). Following on observations that vivax malaria was rare in Africa (6), Miller et al. performed definitive in vivo studies to show that Duffy-negative people resisted, whereas Duffy-positive people were susceptible, to experimental *P. vivax* blood-stage infection following exposure to infected mosquitoes (7). This seminal work, and related *Plasmodium knowlesi* in vitro studies (7–9), established the paradigm that malaria parasites invade erythrocytes through specific “receptor”-based interactions and that the Duffy blood group was the receptor for *P. vivax*.

Resolution of molecular genetic factors responsible for Duffy blood group phenotypes has since been achieved. Erythrocyte Duffy negativity is explained by a single-nucleotide polymorphism (SNP) in a GATA-1 transcription factor binding site of the gene promoter

(–33T → C) that governs erythroid expression (10). Variant antigens Fy^a, Fy^b, and Fy^{bweak} are associated with SNPs in the gene's coding region (11–14). Parallel studies identifying the *P. vivax* Duffy binding protein (PvDBP) (15–17) have provided the opportunity to dissect further the molecular interactions between parasite and host originally predicted by Miller (18, 19).

With the availability of molecular diagnostics, observations of *P. vivax* PCR-positive, Duffy-negative individuals have been made (20–22). PCR-positive samples have been reported in Brazil where there is significant admixture of Duffy-negative and Duffy-positive individuals (20, 21). However, the key biological evidence showing erythrocytes infected by *P. vivax* has not been provided. Indeed, PCR could potentially detect *P. vivax* merozoites released into the bloodstream by infected hepatocytes that are susceptible to the mosquito-transmitted sporozoites. Positive PCR is therefore not synonymous with presence of intraerythrocytic parasites. A recent Kenya-based study reported *P. vivax*-positive *Anopheles* mosquitoes within Duffy-negative populations and low density, microscopically positive blood smears in Duffy-negative children, which could not be confirmed (22). To follow these observations, a survey of >2,500 blood samples from West and central Africans living in nine malaria-endemic countries was conducted to evaluate the prevalence of *Plasmodium falciparum*, *P. vivax*, *Plasmodium malariae*, and *Plasmodium ovale*. Results found only one *P. vivax*-positive sample from a Duffy-positive individual and the authors concluded that low numbers of Duffy positives in Africa are sufficient to maintain *P. vivax* transmission (23). Thus, the question of *P. vivax* blood-stage infection of Duffy-negative individuals in areas where Duffy-positive and -negative populations are established remains open.

Madagascar, the world's fourth largest island 250 miles off the East African coast, has been peopled by successive Austronesian and African migrations over the past 2,300 years (24, 25) (*SI Appendix A, Figs. S1 and S2*). There, potential exists for significant admixture among Duffy blood group phenotypes [Fy(a+b+), Fy(a+b–), Fy(a–b+), Fy(a–b–), Fy(a+b^{weak}); nomenclature descri-

Author contributions: D.M., C. Barnadas, A.R., C.L.K., O.M.-P., and P.A.Z. designed research; D.M., C. Barnadas, C. Bouchier, C.H.-H., L.R.G., A.R., V.T., J.-F.C., O.D., O.B., J.P., and B.T.G. performed research; C.H.-H., Y.C., C.L.K., and P.A.Z. contributed new reagents/analytic tools; D.M., C. Barnadas, C.H.-H., Y.C., O.B., C.L.K., O.M.-P., and P.A.Z. analyzed data; and D.M., C. Barnadas, Y.C., C.L.K., O.M.-P., and P.A.Z. wrote the paper.

The authors declare no conflict of interest.

This article is a PNAS Direct Submission.

Data deposition: The sequences reported in this paper have been deposited in the GenBank database (accession nos. GU130196 and GU130197).

¹D.M. and C. Barnadas contributed equally to this work.

²To whom correspondence may be addressed. E-mail: dmenard@pasteur.fr, omp@pasteur.fr, or paz@case.edu.

This article contains supporting information online at www.pnas.org/cgi/content/full/0912496107/DCSupplemental.

bed in *SI Appendix B, Table S1*], providing Duffy-negative individuals consistent natural exposure to infection by *P. vivax*. In this island biogeographical context, where species are subjected to unique selective pressures, we investigated the relationship between Duffy blood group polymorphism and *P. vivax* blood-stage infection and clinical malaria.

Results

Duffy Genotyping and *Plasmodium* Species Diagnosis. Among 2,112 asymptomatic school children seen at eight sites (February–April 2007), 709 were randomly selected. Of these, 382 (53.8%) children were self-identified to be of Asian origin, and 327 indicated they were of African origin. Both Duffy genotyping and *Plasmodium* species diagnostic assays were performed successfully for 661 children (*Table S2*). Overall, 72.0% (476/661) were genotyped as Duffy negative ($FY^*B^{ES}/*B^{ES}$) and 28% (185/661) were Duffy positive (17.7% $FY^*A/*B^{ES}$, 4.7% $FY^*B/*B^{ES}$, 3.8% $FY^*A/*A$, 1.7% $FY^*A/*B$, and 0.1% $FY^*B/*B$). Prevalence of each *Plasmodium* species was 16.2% *P. falciparum*, 13.0% *P. vivax*, 3.6% *P. ovale*, and 1.8% *P. malariae*; 5.2% of participants were infected with multiple species. Among Duffy-negative individuals 42 (8.8%) were *P. vivax* PCR positive based on the small subunit (SSU) rDNA assay, 32 of which were characterized as *P. vivax* mono-infections. All 42 *P. vivax* infections were confirmed by additional *Plasmodium* species PCR assays based on cytochrome oxidase I (COI) and/or PvDBP (*SI Appendix C*). *P. vivax* infection and Duffy genotype distribution among the school-age children are summarized in Fig. 1. Results show that the highest number of Duffy-negative individuals PCR positive for *P. vivax* were observed at Tsiroanomandidy ($n = 30$) and Miandrivazo ($n = 9$), study sites with the highest frequencies of Duffy-positive study participants (47.2 and 31.8%, respectively).




Fig. 1. Frequency distribution of *P. vivax* infections and clinical cases identified in Duffy-positive and -negative Malagasy people. Pie graphs show the prevalence of Duffy-positive (dark/light green) and Duffy-negative (red/pink quadrants) phenotypes in the eight Madagascar study sites. Prevalence of *P. vivax* infection observed in the survey of school-age children is shown in red and dark green; population subsets not infected with *P. vivax* are pink and light green. Study sites identified by a red star indicate that clinical *vivax* malaria was observed in Duffy-negative individuals (additional data classify clinical cases as numbers of people diagnosed with mono-infection *P. vivax*/mixed *P. vivax* + *P. falciparum*). A green star indicates that *vivax* malaria was observed in Duffy-positive individuals only (Ejeda). In Ihoso clinical malaria was observed in one individual with a mixed *P. vivax*/*P. falciparum* infection. *P. vivax* malaria was not observed in Andapa and Farafangana (black star). Malaria transmission strata are identified as tropical (lightest gray), sub-desert (light gray), equatorial (middle gray), and highlands (dark gray).

Interestingly, in individual study sites with sufficient numbers of PCR-positive *P. vivax* infections to enable comparisons, prevalence ratios were not significantly different between Duffy-positive and -negative children (Tsiroanomandidy χ^2 , 1 df = 2.87, $P = 0.09$; Miandrivazo χ^2 , 1 df = 0.116, $P = 0.733$; Maevatanana χ^2 , 1 df = 1.18, $P = 0.278$). In contrast to these village-specific findings, when considering all 661 school children surveyed, Duffy-negatives were still 3-fold less likely to experience a *P. vivax* blood stage infection compared to Duffy-positive children (Odds ratio = 0.310, 95% confidence interval 0.195–0.493; $P < 0.001$).

Intraerythrocytic *P. vivax* Infection and Clinical Malaria in Duffy Negatives. One hundred eighty-three *P. vivax*-infected samples were collected in 2006/2007 from febrile individuals seeking malaria treatment from health facilities (26). Among these, 153 carried *P. vivax* mono-infections and 30 were *P. vivax*/*P. falciparum* mixed infections. Of the patients experiencing clinical malaria, 17 Duffy-negative individuals from five of the study sites (Fig. 1, red stars; *Table S3*) were *P. vivax* infected. Whereas 8 of these malaria patients were infected with *P. vivax* in the context of a mixture of *Plasmodium* species, 9 were judged to be infected with only *P. vivax* by combined conventional blood smear and PCR-based *Plasmodium* species diagnoses. With 5.9% (9/153) of clinical *P. vivax* mono-infection malaria experienced by Duffy negatives vs. 94.1% (144/153) by Duffy positives, Duffy negativity conferred a >15-fold reduction in prevalence to *P. vivax* malaria.

Standard blood smear microscopy showed evidence of intraerythrocytic infection in four individuals by examining Giemsa-stained slides (Fig. 2). Classic morphological features of *P. vivax* trophozoites (Fig. 2A and B) and *P. vivax* gametocytes (Fig. 2C–F) were observed. Results showing both male and female gametocytes within the same infection suggest that *P. vivax* transmission from Duffy-negative people is possible.

Erythrocyte Duffy-Negative Genotype and Phenotype Concordance.

Further evaluation of 43 Tsiroanomandidy school children was performed to confirm concordance between Duffy genotypes and phenotypes using conventional serology, flow cytometry, and adsorption–elution methods. Comparison of Duffy genotyping with serology was 100% concordant for all Duffy positive/negative and Fy^a/Fy^b antigenic classifications. Fig. 3 illustrates flow cytometry phenotypes comparing control donors and field samples. Fig. 3A shows mean fluorescence intensities (MFI) that reflect binding of the Duffy antigen-specific anti- Fy^b antibody (NaM185-2C3) for well-characterized control donors who were $FY^*B^{ES}/*B^{ES}$ [$Fy(a-b-)$], $FY^*B^{ES}/*X$ [$Fy(a-b^{weak})$], $FY^*X/*X$ [$Fy(a-b^{weak})$], $FY^*A/*B^{ES}$ [$Fy(a+b-)$], and $FY^*A/*B$ [$Fy(a+b+)$], respectively. Additionally, Fig. 3A shows that flow cytometry results for one $FY^*B^{ES}/*B^{ES}$ Malagasy donor were identical to the West African $FY^*B^{ES}/*B^{ES}$ [$Fy(a-b-)$] control and the isotype background control, confirming no erythrocyte surface expression of the extracellular amino terminus of the protein known to mediate invasion of *vivax* merozoites. Fig. 3B shows results for 40 Malagasy individuals, with 30 samples genotyped $FY^*B^{ES}/*B^{ES}$ [$Fy(a-b-)$], 6 genotyped $FY^*A/*B^{ES}$ [$Fy(a+b-)$], 2 genotyped $FY^*A/*A$ [$Fy(a+b-)$], and 2 genotyped $FY^*A/*B$ [$Fy(a+b+)$]. Results show that Duffy antigen expression was uniformly absent from erythrocyte surfaces of all $FY^*B^{ES}/*B^{ES}$ individuals; flow cytometry phenotypes for the Duffy-positive donors showed expected patterns of anti- Fy^b antibody binding. To ascertain that ablated serological detection of Duffy was not due to a mutation in the epitope-coding sequence, >2,550 bp of the Duffy gene were sequenced for 14 Duffy-negative Malagasy study participants who had experienced *P. vivax* clinical malaria (included proximal promoter and full coding sequence; GenBank accession nos. GU130196 and GU130197). This sequencing showed identity between Duffy-negative Malagasy alleles and three West African FY^*B^{ES} alleles and the FY^*B^{ES} GenBank




Fig. 2. Standard Giemsa-stained thin smear preparations of *P. vivax* infection and development in human Duffy-negative erythrocytes. A–C originated from a 4-year-old female, genotyped as Duffy negative ($FY*B^{ES}/*B^{ES}$), who presented at the Tsiroanomandidy health center (June 26, 2006) with fever (37.8 °C), headache, and sweating without previous antimalarial treatment. Standard blood smear diagnosis revealed a mixed infection with *P. vivax* [parasitemia = 3,040 parasitized red blood cells (pRBC)/ μ L] and *P. falciparum* (parasitemia = 980 pRBC/ μ L). PCR-based *Plasmodium* species diagnosis confirmed the blood smear result; *P. malariae* and *P. ovale* were not detected. A shows an undifferentiated *P. vivax* trophozoite with enlarged erythrocyte volume, clear evidence of Schüffner stippling, and amoeboid morphology. B shows a *P. vivax* early stage trophozoite with condensed chromatin, enlarged erythrocyte volume, Schüffner stippling, and irregular ring-shaped cytoplasm. C shows a *P. vivax* gametocyte: Lavender parasite, larger pink chromatin mass, and brown pigment scattered throughout the cytoplasm are characteristics of microgametocytes (male). D originated from a 12-year-old Duffy-negative ($FY*B^{ES}/*B^{ES}$) male, who presented at the Miandrivazo health center (June 27, 2006) with fever (37.5 °C) and shivering without previous antimalarial treatment. Standard blood smear diagnosis and light microscopy revealed infection with only *P. vivax* (parasitemia = 3,000 pRBC/ μ L). PCR-based *Plasmodium* species diagnosis confirmed this blood smear result; *P. falciparum*, *P. malariae*, and *P. ovale* were not detected. The parasite featured shows evidence of a *P. vivax* gametocyte: Large blue parasite, smaller pink chromatin mass, and brown pigment scattered throughout the cytoplasm are characteristics of macrogametocytes (female). E and F originated from a 3-year-old Duffy-negative ($FY*B^{ES}/*B^{ES}$) female, who presented at the Moramanga health center (April 11, 2006) with fever (37.8 °C) without previous antimalarial treatment. Standard blood smear diagnosis and light microscopy revealed infection with only *P. vivax* (parasitemia = 3,368 pRBC/ μ L). PCR-based *Plasmodium* species diagnosis confirmed this blood smear result; *P. falciparum*, *P. malariae*, and *P. ovale* were not detected. The parasites featured show additional evidence of *P. vivax* gametocytes.

reference sequence (X85785) (10) and verified that failure to detect the Duffy antigen by serology resulted from the $-33 T \rightarrow C$ GATA-1 promoter mutation of the otherwise unaltered Duffy gene.

***P. vivax* Strains Infecting Duffy-Negative Malagasies.** To evaluate the diversity of *P. vivax* strains we analyzed the circumsporozoite protein (PvCSP) and *P. vivax*-specific microsatellites (27). Positive genotyping of 16 isolates for PvCSP showed the presence of both VK210 and VK247 variants (VK210, $n = 6$; VK247, $n = 1$; VK210 and VK247, $n = 9$). The mean Nei's unbiased expected heterozygosity (H_e) estimated with microsatellite loci (6–13 alleles identified per infection) did not differ significantly between Duffy-positive ($n = 45$) and Duffy-negative ($n = 11$) patients (0.67 ± 0.17 vs. 0.74 ± 0.15 , $n = 11$, $P > 0.05$); Wright's fixation index analysis showed an absence of genetic differentiation between the two populations ($F_{st} = 0.0094$, $P = 0.20$). Results suggest that numerous strains are able to infect both Duffy-negative and -positive individuals.

Discussion

We studied *P. vivax* infection in Madagascar in an admixed human population that included Duffy-positive and -negative people to test whether consistent natural exposure may have provided *P. vivax* with sufficient opportunity to break through the Duffy-negative barrier thought to confer human resistance to *P. vivax* blood-stage infection. We observed eight different Duffy genotypes in the study population, including a high frequency of Duffy negativity (72%), and discovered that a considerable number of Duffy-negative Malagasies were susceptible to *P. vivax* blood-stage infection and clinical vivax malaria. Vivax malaria was most common in study sites where the prevalence of Duffy positivity was highest. Whereas we found that *P. vivax* PCR positivity did not differ between Duffy-positive and -negative people in high prevalence villages (Tsiroanomandidy and Miandrivazo), we observed a significant 3-fold reduction in *P.*

vivax infection in Madagascar overall, and a substantial reduction in prevalence of clinical *P. vivax* malaria among Duffy negatives compared to Duffy positives. These findings suggest that *P. vivax* invasion of Duffy-negative erythrocytes may be somewhat impaired relative to invasion of Duffy-positive individuals, preventing development of higher parasitemia associated with clinical disease in many individuals.

Human settlement of Madagascar from populations participating in the Indian Ocean trade network beginning $\approx 2,000$ years ago may have been responsible for introducing *P. vivax* into Madagascar by infected immigrants from Southeast Asia (SI Appendix A). Increase in human population density would have provided conditions to sustain *P. vivax* transmission. It is unlikely that *P. vivax* would cause blood-stage infection in Duffy negatives initially. However, a consistent supply of parasites available from infected Duffy-positive Malayo-Indonesians would have provided ample opportunity for infection of hepatocytes of Duffy negatives and selection of *P. vivax* strains with a new capacity for erythrocyte invasion. A report that the so-called Madagascar *P. vivax* strain (28) caused blood-stage infection in one Liberian individual (2) may provide evidence of unique *P. vivax* evolution in Madagascar consistent with our findings, although the Duffy phenotype of the susceptible Liberian was not established.

Whereas new combinations of mutations or altered gene expression could have resulted from population admixture and subsequent recombination between Duffy-negative and -positive alleles in the study participants, Duffy gene sequence analysis and flow cytometry results provide no evidence that a Duffy receptor is available on erythrocyte surfaces of genotypically Duffy-negative ($FY*B^{ES}/*B^{ES}$) Malagasies. Thus *P. vivax* strains infecting Duffy negatives in this study would have required a Duffy-independent mechanism for erythrocyte invasion.

Interestingly, observations of *P. vivax* infection of nonhuman primate erythrocytes and human infection by the related *P. knowlesi* may provide insight regarding an alternative invasion mechanism.




Fig. 3. Flow cytometry and serological correlation of Duffy-negative and Duffy-positive phenotypes with respective genotypes in Malagasy school children from Tsiroanomandidy, Madagascar. (A) Flow cytometric analysis of Duffy blood group genotypes. Flow cytometry histograms show MFI that reflect binding of the Duffy antigen-specific anti-Fy6 antibody (NaM185-2C3) for one Malagasy genotyped as *FY*B^{ES}/X* [Fy(a-b-)] (red) and five well-characterized control donors who are *FY*B^{ES}/X* [Fy(a-b^{weak})] (solid black), *FY*B^{ES}/X* [Fy(a-b^{weak})] (light green), *FY*X/X* [Fy(a-b^{weak})] (green), *FY*A/^{*}B^{ES}* [Fy(a+b-)] (light blue), and *FY*A/*B* [Fy(a+b+)] (blue), respectively. Results include fluorescence of a Duffy-positive blood sample incubated with an isotype control antibody (dotted black line). (B) Flow cytometry of Duffy antigen expression on erythrocytes from 40 Malagasy study participants. Flow cytometry results show MFI that reflect binding of the Duffy antigen-specific anti-Fy6 antibody for 30 *FY*B^{ES}/^{*}B^{ES}* [Fy(a-b-)] Malagasy samples (mean = 48, SD = 1.2), 6 *FY*A/*B^{ES}* [Fy(a+b-)] Malagasy samples (mean = 1,025, SD = 22.4), 2 *FY*A/*A* [Fy(a+b-)] Malagasy samples (mean = 1,937, SD = 54) and 2 *FY*A/*B* [Fy(a+b+)] Malagasy samples (mean = 1,896, SD = 8).

P. vivax readily infects erythrocytes of the squirrel monkey (*Saimiri boliviensis*) (29, 30). Whereas squirrel monkeys express an Fy6-positive Duffy antigen (29–31), the *P. vivax* DBP binds poorly, if at all, to squirrel monkey erythrocytes (32), suggesting a PvDBP-independent invasion mechanism. In vitro studies showing that *P. knowlesi* invades Duffy-negative erythrocytes treated with trypsin and neuraminidase (33) suggest that *P. knowlesi* possess additional erythrocyte invasion ligands enabling Duffy-independent blood-stage infection. Whether our results signal local evolution of a new *P. vivax* erythrocyte invasion pathway, or indicate the existence of yet-uncharacterized erythrocyte invasion mechanisms involving DBPs and/or reticulocyte binding proteins (34, 35), remains to be clarified.

With accumulating reports on severe *P. vivax* morbidity and mortality there is a growing appreciation that this parasite exerts considerable selective pressure on human health (36). Meanwhile, debate persists regarding the evolutionary relationship between *P. vivax* and Duffy negativity. Observations of *P. vivax* PCR positivity in Duffy-negative people add support for alternative receptors (20–22). In contrast, the observation that carriers of the Papua New Guinea Duffy-negative allele (*FY*A^{ES}*) (37) experience reduced *P. vivax* blood-stage infection (38) underscores the strong dependence this parasite displays on Duffy-dependent invasion.

Our observations in Madagascar showing conclusive evidence that *P. vivax* is capable of causing blood-stage infection and disease in Duffy-negative people illustrate that in some conditions *P. vivax* exhibits a capacity for infecting human erythrocytes without the Duffy antigen. The data assembled in this study suggest that conditions needed to clear the barrier of Duffy negativity may include an optimal human admixture. In Madagascar with significant numbers of Duffy-positive people and full susceptibility of hepatocytes in Duffy negatives, *P. vivax* may have sufficient exposure to Duffy-negative erythrocytes, allowing more opportunities for de novo se-

lection or optimization of an otherwise cryptic invasion pathway that nevertheless seems less efficient than the Duffy-dependent pathway.

Finally, given our observations in Madagascar and those from South America and Kenya, a better understanding of the alternative pathways *P. vivax* uses to invade human erythrocytes should become a priority. As current *P. vivax* vaccine strategies focused on PvDBP attempt to exploit Duffy-dependent invasion (39), these collected findings emphasize the importance of a multivalent vaccine strategy that can reduce the potential for parasite strains to escape immunologic control focused on a single protein and a single erythrocyte invasion pathway.

Materials and Methods

Populations and Conventional Parasite Diagnosis. Human subjects protocols (007/SANPF/2007 and 156/SANPFPS/2007) were approved by the Madagascar Ministry of Health, National Ethics Committee; genotyping was performed following a University Hospitals Case Medical Center Institutional Review Board protocol (08-03-33). A cross-sectional survey to evaluate erythrocyte polymorphisms associated with malaria susceptibility was conducted among Malagasy school children in 2007 (40). Children (3–13 years) were recruited at eight study sites, representing the four malaria epidemiological strata of Madagascar (*SI Appendix A*), using a two-level cluster random sampling method (school and classroom). After obtaining informed consent from parents/guardians, whole blood (5 mL) was collected (K⁺-EDTA Vacutainers) by venipuncture from each child. In March 2009 additional blood samples were collected from the same Tsiroanomandidy study population.

In vivo efficacy studies on antimalarial drugs were conducted in 2006 and 2007 at the eight study sites (registration no. ISRCTN36517335) (26, 27). *P. vivax* clinical samples, collected on filter paper, were selected from all patients screened by a rapid diagnostic test (RDT) (OptiMAL-IT; Diamed AG). Giemsa-stained thin/thick blood films were prepared for each RDT-positive patient to check both *Plasmodium* species identification and parasite densities. All patients enrolled in these studies were >6 months old, judged to be *P. vivax* positive with parasite densities ≥250/μL, and had a history of fever (axillary temperature ≥37.5 °C) 48 h before recruitment. Patients displaying mixed infections with *P. vivax* and *P. falciparum* were treated according to the new National Malaria Policy, with a combination of artesunate and amodiaquine (Arsucam) (41). An enrollment questionnaire administered to each patient included history of fever, prior treatment, age, gender, location of habitation, and ethnicity.

DNA Extraction. DNA was extracted from blood spots with Instagene Matrix resin (BioRad) or directly from whole blood (100 μL) using proteinase K/phenol-chloroform.

Molecular Diagnosis. Molecular diagnosis evaluating SNP (Duffy –33, promoter ±; codon 42, *FY*A* vs. *FY*B*) was performed using a post-PCR ligase detection reaction–fluorescent microsphere assay (LDR-FMA) or direct sequencing of PCR products (*SI Appendix C*).

Plasmodium species identification from school children was performed using a PCR-based SSU rRNA assay (42). Asymptomatic *P. vivax* infections were confirmed for each Duffy-negative sample using PCR-based assays for COI and PvDBP. *P. vivax* population diversity was evaluated using PvCSP and microsatellite markers (27). *Plasmodium* species identification from clinical samples was performed using real-time (43) and classical PCR (44).

Duffy Phenotyping. Duffy phenotyping was performed using fresh blood samples collected in March 2009. Duffy antigens (Fy^a/Fy^b) were phenotyped using a microtyping kit and antisera (DiaMed-ID Microtyping System), following manufacturer’s instructions. Expression of Duffy antigen on erythrocytes was evaluated by flow cytometry (BD FACS Canto II flow cytometer; Becton Dickinson) using monoclonal antibodies: F655 antibody (Fy^a specific), Hiro31 antibody (Fy^b specific), and anti-Fy6 antibody (NaM185-2C3 clone, Duffy specific) (45). Briefly, erythrocytes from EDTA-anticoagulated field and control samples [Fy(a+b-), Fy(a-b+), Fy(a+b+), and Fy(a-b^{weak})]; obtained from the Centre National de Référence pour les Groupes Sanguins, Paris] were washed twice in phosphate buffer solution (PBS). Cells were then resuspended with isotype controls IgG/IgM (5 μg/mL; BD) or monoclonal antibodies (anti-Fy6 diluted at 1:8, Hiro31 and F655 diluted at 1:4) at room temperature for 1 h in PBS/0.1% BSA solution. After primary incubation, cells were washed twice in PBS and incubated in the dark at room temperature for 1 h with secondary phycoerythrin (PE) antibody (Beckman Coulter) at a concentration of 5 μg/mL in PBS/0.1% BSA solution. After a final wash in PBS, cells were

acquired by a digital high speed analytical flow cytometer. Erythrocytes were identified on the basis of forward/side scatter characteristics, using logarithmic amplification. After excitation at 488 nm, PE signal was collected with a 585/42 band pass filter. Data were acquired by BD FACS Diva software (v6.1.2) and analyzed using FlowJo (TreeStar) software v7.2.5. Final controls of erythrocyte Duffy antigen expression were performed using adsorption-elution experiments (14).

Population Genetic Analyses. Genetic diversity was assessed by Nei's unbiased expected heterozygosity (H_e) from haploid data and calculated as $H_e = [n/(n-1)] [1 - \sum p_i^2]$ (n is the number of isolates sampled; p_i^2 is the frequency of the i th allele) (46). Population genetic differentiation between symptomatic Duffy negatives and positives was measured using Wright's F statistics (47); population genetic parameters were computed with FSTAT software, v2.9.4 (48).

ACKNOWLEDGMENTS. We thank the school children and their parents/guardians for participating in the study, administrative staff and teachers, and Circonscription Scolaire chiefs who helped us with study organization. We thank the patients and

health care workers involved in the national network for malaria resistance surveillance in Madagascar (Réseau d'Etude de la Résistance) and staff of the Madagascar Ministry of Health. We thank L. Randrianasolo, R. Raheerinjafy, A. Randriamanantena, H. Ranaivosoa, D. Ralaizandry, D. Raveloariseheno, V. Rabekotorina, R. Razakandrainibe, E. Rakotomalala, H. Andrianantenaina, O. Voahanginirina, T. Eugénie Rahasana, A. Contamin, and L. Fanazava for helping with field work. We especially thank B. Contamin (Fondation Mérieux, Lyon) and M. Noelle Ungeheuer (Clinical Investigation and Biomedical Research Support Unit, Institut Pasteur, Paris). We thank Dr. B. N. Pham and E. Vera (Centre National de Référence pour les Groupes Sanguins) for frozen blood sample management and fixation/elution experiments and M. Tichit (Institut Pasteur, Paris) for DNA sequencing. This study was supported by the BioMalPar European Network of Excellence (LSHP-CT-2004-503578) from the Priority 1 "Life Sciences, Genomics and Biotechnology for Health" in the 6th Framework Programme, from Plate-forme Génomique (Génopôle, Institut Pasteur, Paris); by the U.S. National Institutes of Health (AI46919 and TV007872); and by the Global Fund (MDG-304-G05-M) and Veterans' Affairs Research Service. C. Barnadas received postdoctoral fellowship support from Fondation Mérieux (Lyon, France). V. Thonier was supported by an "année-recherche" grant from the Direction des Affaires Sanitaires et Sociales of the Rhone Alpes.

1. Boyd MF, Stratman-Thomas WK (1933) Studies on benign tertian malaria. 4. On the refractoriness of negroes to inoculation with *Plasmodium vivax*. *Am J Hyg* 18:485-489.
2. Bray RS (1958) The susceptibility of Liberians to the Madagascar strain of *Plasmodium vivax*. *J Parasitol* 44 (4, Sect 1):371-373.
3. O'Leary PA (1927) Treatment of neurosyphilis by malaria: Report on the three years' observation of the first one hundred patients treated. *J Am Med Assoc* 89:95-100.
4. Zimmerman PA (2004) *Infectious Disease and Host-Pathogen Evolution*, ed Dronamraju KR (Cambridge Univ Press, New York), pp 141-172.
5. Roychoudhury AK, Nei M (1988) *Human Polymorphic Genes: World Distribution* (Oxford Univ Press, New York).
6. Escudie A, Hamon J (1961) [Malaria in French West Africa.]. *Med Trop (Mars)* 21 (Special):661-687.
7. Miller LH, Mason SJ, Clyde DF, McGinniss MH (1976) The resistance factor to *Plasmodium vivax* in blacks. The Duffy-blood-group genotype, FyFy. *N Engl J Med* 295:302-304.
8. Miller LH, et al. (1977) Evidence for differences in erythrocyte surface receptors for the malarial parasites, *Plasmodium falciparum* and *Plasmodium knowlesi*. *J Exp Med* 146:277-281.
9. Miller LH, Mason SJ, Dvorak JA, McGinniss MH, Rothman IK (1975) Erythrocyte receptors for (*Plasmodium knowlesi*) malaria: Duffy blood group determinants. *Science* 189:561-563.
10. Tournamille C, Colin Y, Cartron JP, Le Van Kim C (1995) Disruption of a GATA motif in the Duffy gene promoter abolishes erythroid gene expression in Duffy-negative individuals. *Nat Genet* 10:224-228.
11. Iwamoto S, Omi T, Kajii E, Ikemoto S (1995) Genomic organization of the glycoprotein D gene: Duffy blood group Fya/Fyb alloantigen system is associated with a polymorphism at the 44-amino acid residue. *Blood* 85:622-626.
12. Olsson ML, et al. (1998) The Fy(x) phenotype is associated with a missense mutation in the Fy(b) allele predicting Arg89Cys in the Duffy glycoprotein. *Br J Haematol* 103:1184-1191.
13. Tournamille C, Le Van Kim C, Gane P, Cartron JP, Colin Y (1995) Molecular basis and PCR-DNA typing of the Fya/fyb blood group polymorphism. *Hum Genet* 95:407-410.
14. Tournamille C, et al. (1998) Arg89Cys substitution results in very low membrane expression of the Duffy antigen/receptor for chemokines in Fy(x) individuals. *Blood* 92:2147-2156.
15. Adams JH, et al. (1992) A family of erythrocyte binding proteins of malaria parasites. *Proc Natl Acad Sci USA* 89:7085-7089.
16. Fang XD, Kaslow DC, Adams JH, Miller LH (1991) Cloning of the *Plasmodium vivax* Duffy receptor. *Mol Biochem Parasitol* 44:125-132.
17. Wertheimer SP, Barnwell JW (1989) *Plasmodium vivax* interaction with the human Duffy blood group glycoprotein: Identification of a parasite receptor-like protein. *Exp Parasitol* 69:340-350.
18. Hans D, et al. (2005) Mapping binding residues in the *Plasmodium vivax* domain that binds Duffy antigen during red cell invasion. *Mol Microbiol* 55:1423-1434.
19. Singh SK, Hora R, Belrhali H, Chitnis CE, Sharma A (2006) Structural basis for Duffy recognition by the malaria parasite Duffy-binding-like domain. *Nature* 439:741-744.
20. Cavasini CE, et al. (2007) Duffy blood group gene polymorphisms among malaria vivax patients in four areas of the Brazilian Amazon region. *Malar J* 6:167.
21. Cavasini CE, et al. (2007) *Plasmodium vivax* infection among Duffy antigen-negative individuals from the Brazilian Amazon region: An exception? *Trans R Soc Trop Med Hyg* 101:1042-1044.
22. Ryan JR, et al. (2006) Evidence for transmission of *Plasmodium vivax* among a duffy antigen negative population in Western Kenya. *Am J Trop Med Hyg* 75:575-581.
23. Culleton RL, et al. (2008) Failure to detect *Plasmodium vivax* in West and Central Africa by PCR species typing. *Malar J* 7:174.
24. Burney DA, et al. (2004) A chronology for late prehistoric Madagascar. *J Hum Evol* 47:25-63.
25. Hurler ME, Sykes BC, Jobling MA, Forster P (2005) The dual origin of the Malagasy in Island Southeast Asia and East Africa: Evidence from maternal and paternal lineages. *Am J Hum Genet* 76:894-901.
26. Barnadas C, et al. (2008) *Plasmodium vivax* resistance to chloroquine in Madagascar: Clinical efficacy and polymorphisms in pvmr1 and pvcrt-o genes. *Antimicrob Agents Chemother* 52:4233-4240.
27. Barnadas C, et al. (2008) *Plasmodium vivax* dhfr and dhps mutations in isolates from Madagascar and therapeutic response to sulphadoxine-pyrimethamine. *Malar J* 7:35.
28. Shute PG, Garnham PCC, Maryon M (1980) The Madagascar strain of *Plasmodium vivax*. *Arch Inst Pasteur Madagascar* 47:173-183.
29. Barnwell JW, Nichols ME, Rubinstein P (1989) In vitro evaluation of the role of the Duffy blood group in erythrocyte invasion by *Plasmodium vivax*. *J Exp Med* 169:1795-1802.
30. Nichols ME, Rubinstein P, Barnwell J, Rodriguez de Cordoba S, Rosenfield RE (1987) A new human Duffy blood group specificity defined by a murine monoclonal antibody. Immunogenetics and association with susceptibility to *Plasmodium vivax*. *J Exp Med* 166:776-785.
31. Tournamille C, et al. (2004) Sequence, evolution and ligand binding properties of mammalian Duffy antigen/receptor for chemokines. *Immunogenetics* 55:682-694.
32. Tran TM, et al. (2005) Detection of a *Plasmodium vivax* erythrocyte binding protein by flow cytometry. *Cytometry A* 63:59-66.
33. Mason SJ, Miller LH, Shiroishi T, Dvorak JA, McGinniss MH (1977) The Duffy blood group determinants: Their role in the susceptibility of human and animal erythrocytes to *Plasmodium knowlesi* malaria. *Br J Haematol* 36:327-335.
34. Galinski MR, Medina CC, Ingravallo P, Barnwell JW (1992) A reticulocyte-binding protein complex of *Plasmodium vivax* merozoites. *Cell* 69:1213-1226.
35. Carlton JM, et al. (2008) Comparative genomics of the neglected human malaria parasite *Plasmodium vivax*. *Nature* 455:757-763.
36. Baird JK (2009) Resistance to therapies for infection by *Plasmodium vivax*. *Clin Microbiol Rev* 22:508-534.
37. Zimmerman PA, et al. (1999) Emergence of FY*A(null) in a *Plasmodium vivax*-endemic region of Papua New Guinea. *Proc Natl Acad Sci USA* 96:13973-13977.
38. Kasehagen LJ, et al. (2007) Reduced *Plasmodium vivax* erythrocyte infection in PNG Duffy-negative heterozygotes. *PLoS One* 2:e336.
39. Galinski MR, Barnwell JW (2008) *Plasmodium vivax*: Who cares? *Malar J* 7 (Suppl 1): S9.
40. Razakandrainibe R, et al. (2009) Epidemiological situation of malaria in Madagascar: Baseline data for monitoring the impact of malaria control programmes using serological markers. *Acta Trop* 111:160-167.
41. Programme National de Lutte contre le Paludisme (2005) *Politique Nationale de Lutte contre le Paludisme a Madagascar* (Ministère de la Santé et du Planning Familial, Antananarivo, Madagascar), p 44.
42. McNamara DT, Thomson JM, Kasehagen LJ, Zimmerman PA (2004) Development of a multiplex PCR-ligase detection reaction assay for diagnosis of infection by the four parasite species causing malaria in humans. *J Clin Microbiol* 42:2403-2410.
43. de Monbrison F, Angei C, Staal A, Kaiser K, Picot S (2003) Simultaneous identification of the four human *Plasmodium* species and quantification of *Plasmodium* DNA load in human blood by real-time polymerase chain reaction. *Trans R Soc Trop Med Hyg* 97:387-390.
44. Singh B, et al. (1999) A genus- and species-specific nested polymerase chain reaction malaria detection assay for epidemiologic studies. *Am J Trop Med Hyg* 60:687-692.
45. Wasniowska K, et al. (2002) Structural characterization of the epitope recognized by the new anti-Fy6 monoclonal antibody NaM 185-2C3. *Transfus Med* 12:205-211.
46. Nei M (1978) Estimation of average heterozygosity and genetic distance from a small number of individuals. *Genetics* 89:583-590.
47. Wright S (1965) The interpretation of population structure by F-statistics with special regard to systems of mating. *Evolution* 19:395-420.
48. Goudet J (2003) Fstat (Version 2.9.4), a Program to Estimate and Test Population Genetics Parameters. Updated from Goudet (1995). Available from <http://www.unil.ch/izea/software/fstat.html>.